BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1500026)

  • 1. Preoperative serum CA-125 levels in borderline tumors of the ovary.
    Rice LW; Lage JM; Berkowitz RS; Goodman A; Muto MG; Knapp RC; Bell DA
    Gynecol Oncol; 1992 Aug; 46(2):226-9. PubMed ID: 1500026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial ovarian tumors of borderline malignancy.
    Rice LW; Berkowitz RS; Mark SD; Yavner DL; Lage JM
    Gynecol Oncol; 1990 Nov; 39(2):195-8. PubMed ID: 2227595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors).
    Gundogdu F; Soylu F; Erkan L; Tatli O; Mavi S; Yavuzcan A
    Arch Gynecol Obstet; 2011 Jun; 283(6):1397-402. PubMed ID: 20645105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial ovarian carcinoma of low malignant potential.
    Darai E; Teboul J; Walker F; Benifla JL; Meneux E; Guglielmina JN; Pennehouat G; Renolleau C; Sebban E; Madelenat P
    Eur J Obstet Gynecol Reprod Biol; 1996 Jun; 66(2):141-5. PubMed ID: 8735736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases.
    Bostwick DG; Tazelaar HD; Ballon SC; Hendrickson MR; Kempson RL
    Cancer; 1986 Nov; 58(9):2052-65. PubMed ID: 3756820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
    Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinicopathological features and risk factors of recurrence in patients with mucinous borderline ovarian tumors].
    Sun L; Song Y; Li N; Yuan GW; Sun YC; Li N; Ma SK; Zhang X; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):589-594. PubMed ID: 28835081
    [No Abstract]   [Full Text] [Related]  

  • 9. CA 125 measurement and ultrasonography in borderline tumors of the ovary.
    Gotlieb WH; Soriano D; Achiron R; Zalel Y; Davidson B; Kopolovic J; Novikov I; Ben-Baruch G
    Am J Obstet Gynecol; 2000 Sep; 183(3):541-6. PubMed ID: 10992171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
    Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
    Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
    Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
    Prat J; De Nictolis M
    Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
    Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
    Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
    Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.
    Lee KR; Scully RE
    Am J Surg Pathol; 2000 Nov; 24(11):1447-64. PubMed ID: 11075847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas.
    Molina R; Ojeda B; Filella X; Borras G; Jo J; Mas E; Lopez JJ; Ballesta A
    Tumour Biol; 1992; 13(5-6):278-86. PubMed ID: 1290025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature.
    Kolwijck E; Thomas CM; Bulten J; Massuger LF
    Int J Gynecol Cancer; 2009 Nov; 19(8):1335-8. PubMed ID: 20009886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma.
    Zurawski VR; Knapp RC; Einhorn N; Kenemans P; Mortel R; Ohmi K; Bast RC; Ritts RE; Malkasian G
    Gynecol Oncol; 1988 May; 30(1):7-14. PubMed ID: 2452773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.